Sonus Pharmaceuticals, Inc. Presents Encouraging Phase 2 Efficacy And Safety Data On TOCOSOL(R) Paclitaxel At San Antonio Breast Cancer Symposium

SAN ANTONIO--(BUSINESS WIRE)--Dec. 8, 2005-- Multinational Phase 3 pivotal study evaluating use of TOCOSOL Paclitaxel in metastatic breast cancer treatment ongoing Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) today presented encouraging safety and efficacy data from the Phase 2 clinical program for TOCOSOL(R) Paclitaxel at the San Antonio Breast Cancer Symposium. The data included promising anti-tumor activity in an ongoing Phase 2 trial of 47 women with first-line metastatic breast cancer. TOCOSOL Paclitaxel is an injectable, novel ready-to-use formulation of the widely prescribed anti-cancer drug paclitaxel. Paclitaxel is a member of the taxane group of chemotherapy drugs and is the active ingredient in approved drug products that are used to treat many forms of cancer.